AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 171 min read$RGEN

Garland Jason K sold $80K of RGEN

Garland Jason K (CFO) sold 530 shares of REPLIGEN CORP (RGEN) at $150.00 on 2026-07-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Garland Jason K
Published Jul 17, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 5:50 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$RGEN
Neutral
high confidence
Mentioned
$RGEN
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RGENNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details (530 shares at $150, total $79,500) by the CFO on 2026-07-16, filed on 2026-07-17, under a 10b5-1 plan.

02

Market read

Traders may note the insider sale for sentiment, but the disclosure lacks any fundamental catalyst (no guidance, deal, or regulatory update).

03

What to watch

Insider sales can be driven by diversification or tax planning; the article provides no context on total holdings, option exercises, or other concurrent insider activity.

Relevance 2/10Novelty 3/10Timing: filed 2026-07-17, transaction dated 2026-07-16

Background

The article is a SEC Form 4 insider transaction disclosure for Repligen Corp (RGEN).

Company-level read

Ticker impact

$RGENNeutralHigh confidence
Context

Repligen CFO Garland Jason K filed a Form 4 open-market sale of 530 shares at $150 on 2026-07-16 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited and short-lived.

Evidence & confidence

The filing is a routine 10b5-1 planned open-market sale with modest size ($79.5k) and no accompanying operational or guidance change in the text.

Market effects

Sector

No sector read-through is provided; this appears company-specific and routine.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may not signal reduced confidence and could be ignored by most traders.

Key entities

  • issuer
    REPLIGEN CORP

    Company whose CFO insider sale is disclosed via SEC Form 4.

  • insider
    Garland Jason K

    CFO who executed the open-market sale under a 10b5-1 plan.

Read at source← All news

Related articles

JUL 30
$RGENHighAI 9/10

Repligen Q2 Earnings Call Highlights

Repligen (NASDAQ:RGEN) reported Q2 growth in chromatography revenue in the low double digits, driven by OPUS columns and demand from CDMOs and biopharma. Filtration revenue rose slightly, with headwinds tied to gene therapy issues, ATF customer inventory, site readiness delays, and the Polymem divestiture. Repligen raised 2026 revenue outlook to $813M-$834M and EPS to $2.03-$2.09, excluding BioLife acquisition.

yahoo.com7 min
JUL 28
$RGENMedAI 8/10

Why Repligen (RGEN) Stock Is Up Today

Repligen (NASDAQ: RGEN) shares rose 14.6% after the company reported Q2 results that beat expectations and lifted its full-year outlook. Adjusted EPS was $0.54 vs $0.45 expected, and revenue was $204.1M, up 11.9% year over year. Full-year revenue guidance was raised to about $824M and adjusted EPS to $2.03 to $2.09.

financialcontent.com3 min
JUL 28
$RGENHighAI 8/10

Repligen Stock Jumps As $1.5B BioLife Deal Targets EPS Boost

Repligen (NASDAQ: RGEN) shares rose about 13.77% after the company agreed to buy BioLife Solutions for about $1.5B in a cash-and-stock deal. Management said 64% of consideration is RGEN stock and 36% cash, with closing targeted for Q4 2026. The deal is expected to be accretive, with at least $0.05 adjusted EPS in year one and $0.25 in year two, plus $20M-$30M synergies over two years.

stockstotrade.com5 min
JUL 28
$RGENMedAI 9/10

RGEN Q2 FY2026 earnings call — BigGo Finance

Repligen (RGEN) reported Q2 FY2026 revenue of $204M, up 12% reported and 13% organic. Adjusted EPS rose 46% to $0.54, with adjusted gross margin up 280 bps to 53.9% and operating margin up 460 bps to 16.7%. The company raised full-year guidance to $2.03-$2.09 adjusted EPS and expects 10.5%-13.5% organic growth, citing order momentum and Proteins/Analytics strength. It also agreed to acquire BioLife, expected to close in Q4 2026.

finance.biggo.com6 min